Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorAguilar, Ariadna
dc.contributor.authorCodina, Claudia
dc.contributor.authorMarín García, Antonio
dc.contributor.authorAlcalá-González, Luis Gerardo
dc.contributor.authorGuillen-Del-Castillo, Alfredo
dc.contributor.authorBarber Caselles, Claudia
dc.contributor.authorMalagelada, Carolina
dc.contributor.authorSimeón-Aznar , Carmen Pilar
dc.date.accessioned2025-01-21T09:26:47Z
dc.date.available2025-01-21T09:26:47Z
dc.date.issued2024-11-27
dc.identifier.citationAlcala-Gonzalez LG, Guillen-Del-Castillo A, Aguilar A, Barber C, Codina C, Marin Garcia A, et al. Impact of gastrointestinal symptoms and psychological distress on quality of life in systemic sclerosis: a cross-sectional study. BMJ Open. 2024 Nov;14:e089725.
dc.identifier.issn2044-6055
dc.identifier.urihttps://hdl.handle.net/11351/12451
dc.descriptionMotility disorders; Psychological Stress; Quality of Life
dc.description.abstractBackground Systemic sclerosis (SSc) is a chronic autoimmune disease characterised by microvascular damage and fibrosis. Mortality in patients with SSc has significantly decreased. Consequently, patients with SSc have longer life expectancy, and health-related quality of life (HrQoL) has become more relevant in the comprehensive management of the disease. Objective To evaluate the impact between gastrointestinal (GI) symptom burden and psychological well-being on HrQoL in patients with SSc. Design Nested cross-sectional study conducted between January and July 2022. Participants A single-centre cohort of 166 patients with SSc, including 103 (55%) with limited cutaneous SSc, 43 (24%) with diffuse SSc and 37 (21%) with sine-sclerosis SSc. Main measures GI symptom burden was assessed using the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA SCTC GIT 2.0) questionnaire, psychological well-being was measured with the Hospital Anxiety and Depression Scale (HADS), and HrQoL was evaluated using the Short Form 36 (SF-36) questionnaire. Demographic, clinical and immunological data were collected from a prospectively maintained database. Key results Patients with moderate to severe GI symptoms (UCLA SCTC GIT 2.0 score >0.5, n=95, 57%) reported decreased HrQoL in all subdomains except vitality by SF-36, and higher anxiety and depression scores by HADS (all p<0.05). The severity of GI symptom burden and depression were independently associated with a decline in the physical component of QoL (β=−0.273 and β=−0.411, respectively, p<0.01 for both). Only the severity of depression and anxiety (β=−0.482 and β=−0.213, respectively, p<0.05), but not GI symptom burden, were independently associated with a decline in the mental component of QoL. Conclusions Our data suggest that in patients with SSc, GI and psychological burden negatively influence quality of life independently, highlighting the need for a holistic approach to patient’s care.
dc.language.isoeng
dc.publisherBMJ
dc.relation.ispartofseriesBMJ Open;14
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectPacients - Satisfacció
dc.subjectEstrès
dc.subjectEsclerosi sistemàtica progressiva
dc.subjectAparell digestiu - Malalties
dc.subject.meshStress, Psychological
dc.subject.meshScleroderma, Systemic
dc.subject.meshGastrointestinal Diseases
dc.subject.meshQuality of Life
dc.titleImpact of gastrointestinal symptoms and psychological distress on quality of life in systemic sclerosis: a cross-sectional study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1136/bmjopen-2024-089725
dc.subject.decsestrés psicológico
dc.subject.decsesclerodermia sistémica
dc.subject.decsenfermedades gastrointestinales
dc.subject.decscalidad de vida
dc.relation.publishversionhttps://doi.org/10.1136/bmjopen-2024-089725
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Gerardo Alcala-Gonzalez L] Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Guillen-Del-Castillo A, Codina C] Servei de Medicina Interna, Unitat d’Inflamació i Autoimmunitat, Àrea de Malalties Autoimmunes Sistèmiques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Aguilar A, Barber C] Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain. [Marin Garcia A] Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Malagelada C] Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Simeon-Aznar CP] Unitat d’Inflamació i Autoimmunitat, Àrea de Malalties Autoimmunes Sistèmiques, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid39609018
dc.identifier.wos001366264400001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F01804
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record